PubRank

K Thielemans

Author PubWeight™ 102.14‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 CD8alpha+ and CD8alpha- subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J Exp Med 1999 6.06
2 Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group. N Engl J Med 1998 4.95
3 The B-cell surface protein CD72/Lyb-2 is the ligand for CD5. Nature 1991 2.76
4 Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation. J Clin Invest 2000 2.67
5 Antigen-pulsed dendritic cells can efficiently induce an antibody response in vivo. J Exp Med 1992 2.05
6 B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J Exp Med 2000 2.02
7 A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 1985 1.91
8 Mouse x human heterohybridomas as fusion partners with human B cell tumors. J Immunol Methods 1986 1.73
9 Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med 1999 1.67
10 Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 1994 1.58
11 Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 1992 1.42
12 Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood 1999 1.37
13 Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br J Cancer 1997 1.30
14 Role of CD8alpha+ and CD8alpha- dendritic cells in the induction of primary immune responses in vivo. J Leukoc Biol 1999 1.30
15 Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther 2006 1.30
16 Biclonal B-cell lymphoma. N Engl J Med 1984 1.27
17 Human dendritic cell responses to lipopolysaccharide and CD40 ligation are differentially regulated by interleukin-10. Eur J Immunol 1997 1.27
18 Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. Gene Ther 2007 1.27
19 Image-based point spread function implementation in a fully 3D OSEM reconstruction algorithm for PET. Phys Med Biol 2010 1.24
20 Interleukin-10 prevents the generation of dendritic cells from human peripheral blood mononuclear cells cultured with interleukin-4 and granulocyte/macrophage-colony-stimulating factor. Eur J Immunol 1997 1.24
21 Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood 1998 1.22
22 Endogenously produced substance P contributes to lymphocyte proliferation induced by dendritic cells and direct TCR ligation. Eur J Immunol 1999 1.16
23 Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. Br J Haematol 1994 1.14
24 Interleukin-12-activated natural killer cells recognize B7 costimulatory molecules on tumor cells and autologous dendritic cells. Blood 1998 1.12
25 A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. Cancer Res 2000 1.12
26 Strategies for production of monoclonal anti-idiotype antibodies against human B cell lymphomas. J Immunol 1984 1.06
27 Decreased CD40 ligand induction in CD4 T cells and dysregulated IL-12 production during HIV infection. Clin Exp Immunol 1999 1.05
28 Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines. Gene Ther 2005 1.05
29 Detection of monoclonal B lymphocytes in bone marrow and peripheral blood of multiple myeloma patients by immunoglobulin gene rearrangement studies. Br J Haematol 1989 1.00
30 A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor. Blood 2000 1.00
31 Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells. Gene Ther 2012 0.99
32 Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J Immunol 1987 0.98
33 CD40 ligation prevents Trypanosoma cruzi infection through interleukin-12 upregulation. Infect Immun 1999 0.97
34 Human pancreatic duct cells can produce tumour necrosis factor-alpha that damages neighbouring beta cells and activates dendritic cells. Diabetologia 2004 0.96
35 Clonally related IgA- and IgE-secreting plasma cells in a myeloma patient. Eur J Haematol 2000 0.95
36 Ly-1 (CD5), a membrane glycoprotein of mouse T lymphocytes and a subset of B cells, is a natural ligand of the B cell surface protein Lyb-2 (CD72). J Immunol 1992 0.94
37 Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity. J Immunol 1999 0.94
38 A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann Oncol 2013 0.94
39 CD40 engagement on endothelial cells promotes tissue factor-dependent procoagulant activity. Thromb Haemost 1998 0.93
40 Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor immunity. Int J Cancer 1998 0.93
41 IL-12 prevents neonatal induction of transplantation tolerance in mice. Eur J Immunol 1998 0.92
42 CD45RO+ memory T cells but not CD45RA+ naive T cells can be efficiently activated by remote co-stimulation with B7. Int Immunol 1993 0.91
43 Expression of B7-1 by highly metastatic mouse T lymphomas induces optimal natural killer cell-mediated cytotoxicity. Cancer Res 1995 0.91
44 Treatment of mice bearing BCL1 lymphoma with bispecific antibodies. J Immunol 1991 0.89
45 CD40L-induced IL-12 production is further enhanced by the Th2 cytokines IL-4 and IL-13. Scand J Immunol 2001 0.89
46 Granulocyte-macrophage colony-stimulating factor: involvement in control of Trypanosoma cruzi infection in mice. Infect Immun 1996 0.88
47 Activation of murine T cells by bacterial superantigens requires B7-mediated costimulation. Cell Immunol 1995 0.88
48 Immunoglobulins D and M multiple myeloma variants are heavily mutated. Clin Cancer Res 1997 0.88
49 CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules. Leukemia 1997 0.87
50 Autoimmune lymphoproliferative syndrome type III, an indefinite disorder. Leuk Lymphoma 2001 0.87
51 Immunoglobulin VH gene sequence analysis of spontaneous murine immunoglobulin-secreting B-cell tumours with clinical features of human disease. Immunology 1998 0.86
52 Co-stimulation lowers the threshold for activation of naive T cells by bacterial superantigens. Int Immunol 1995 0.86
53 The effect of regularization in motion compensated PET image reconstruction: a realistic numerical 4D simulation study. Phys Med Biol 2013 0.84
54 Induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA. Gene Ther 2006 0.83
55 Myeloma isotype-switch variants in the murine 5T myeloma model: evidence that myeloma IgM and IgA expressing subclones can originate from the IgG expressing tumour. Leukemia 2001 0.83
56 Lentiviral vectors: a versatile tool to fight cancer. Curr Mol Med 2013 0.82
57 Inhibition of the CD40 pathway of monocyte activation by triazolopyrimidine. Clin Immunol 1999 0.82
58 Extracting a respiratory signal from raw dynamic PET data that contain tracer kinetics. Phys Med Biol 2014 0.81
59 Production and characterization of bispecific single-chain antibody fragments. Mol Immunol 1995 0.81
60 CD40 engagement induces monocyte procoagulant activity through an interleukin-10 resistant pathway. Eur J Immunol 1996 0.81
61 Vaccination with tumor-antigen-pulsed dendritic cells induces in vivo resistance to a B cell lymphoma. Adv Exp Med Biol 1993 0.81
62 Tumorigenicity of mouse T lymphoma cells is controlled by the level of major histocompatibility complex class I H-2Kk antigens. Clin Exp Metastasis 1994 0.80
63 Effects of granulocyte-macrophage colony-stimulating factor and tumor necrosis factor alpha on Trypanosoma cruzi trypomastigotes. Infect Immun 1998 0.80
64 In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model. J Immunol 1998 0.80
65 Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity. Int J Cancer 1999 0.80
66 Interferon-beta inhibits Th1 responses at the dendritic cell level. Relevance to multiple sclerosis. Acta Neurol Belg 1999 0.79
67 Implementation and evaluation of a 3D one-step late reconstruction algorithm for 3D positron emission tomography brain studies using median root prior. Eur J Nucl Med Mol Imaging 2001 0.79
68 Southern blot analysis in a case of Richter's syndrome. Evidence for a postrearrangement heavy chain gene deletion associated with the altered phenotype. Am J Clin Pathol 1991 0.79
69 IFN-beta interferes with the differentiation of dendritic cells from peripheral blood mononuclear cells: selective inhibition of CD40-dependent interleukin-12 secretion. J Interferon Cytokine Res 1999 0.79
70 Induction of tumor immunity by autologous B lymphoma cells expressing a genetically engineered idiotype. Gene Ther 1999 0.79
71 Downregulation of Stat3 in melanoma: reprogramming the immune microenvironment as an anticancer therapeutic strategy. Gene Ther 2013 0.79
72 Immune changes induced by electroconvulsive therapy (ECT). Ann N Y Acad Sci 1992 0.78
73 Syngeneic antiidiotypic immune responses to a B cell lymphoma. Comparison between heavy chain hypervariable region peptides and intact Ig as immunogens. J Exp Med 1985 0.78
74 The genetic variability of the VH genes in follicular lymphoma: the impact of the hypermutation mechanism. Br J Haematol 1999 0.78
75 Role of T-cell subsets in the bispecific antibody (anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma. Cancer Res 1994 0.78
76 Revision of the diagnosis of T-zone lymphoma in the father of a patient with autoimmune lymphoproliferative syndrome type II. Br J Haematol 1999 0.78
77 Persistence of residual tumour cells after cytokine-mediated ex vivo expansion of mobilized CD34+ blood cells in multiple myeloma. Br J Haematol 1997 0.78
78 Enhanced 3D PET OSEM reconstruction using inter-update Metz filtering. Phys Med Biol 2000 0.78
79 B7-1, IFN gamma and anti-CTLA-4 co-operate to prevent T-cell tolerization during immunotherapy against a murine T-lymphoma. Int J Cancer 2000 0.77
80 Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody. Protein Eng 1996 0.77
81 Native soluble CD5 delivers a costimulatory signal to resting human B lymphocytes. Cell Immunol 1996 0.77
82 Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: increased efficacy with multiple injections and CD28-induced costimulation. Blood 1996 0.77
83 Bispecific antibody therapy of two murine B-cell lymphomas. Int J Cancer Suppl 1992 0.77
84 The clonogenic precursor cell in multiple myeloma. Leuk Lymphoma 1995 0.77
85 Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3). J Immunol 1991 0.77
86 Metastasis of mouse T lymphoma cells is controlled by the level of major histocompatibility complex class I H-2Dk antigens. Int J Cancer 1994 0.76
87 Active antitumor immunotherapy, with or without B7-mediated costimulation, increases tumor progression in an immunogenic murine T cell lymphoma model. Cancer Immunol Immunother 1998 0.76
88 Selective response of CD5+ B cell malignancies to activation of the CD72 antigen. Clin Immunol Immunopathol 1998 0.76
89 Fighting with the enemy's weapons? the role of costimulatory molecules in HIV. Curr Mol Med 2011 0.76
90 Unexpected effects of viral interleukin-10-secreting dendritic cells in vivo: preferential inhibition of TH2 responses. Transplant Proc 2004 0.76
91 Costimulation regulates the kinetics of interleukin-2 response to bacterial superantigens. Immunology 1996 0.75
92 In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma. J Hematother 1995 0.75
93 Use of quantitative ASO-PCR to predict relapse in multiple myeloma. Br J Haematol 1999 0.75
94 Idiotypic vaccination as therapy for multiple myeloma. Semin Hematol 1999 0.75
95 Enhancement of a spontaneous immune response against a B-cell lymphoma by dendritic cells leads to protection against the tumor. Ann N Y Acad Sci 1993 0.75
96 The immunobiology of B cell lymphoma: clonal heterogeneity as revealed by anti-idiotype antibodies and immunoglobulin gene probes. Symp Fundam Cancer Res 1986 0.75
97 Sequence evolution and escape from specific immune pressure of an HIV-1 Rev epitope with extensive sequence similarity to human nucleolar protein 6. Tissue Antigens 2012 0.75
98 Contribution of immunological methods to the diagnosis of hematological malignancies. Acta Clin Belg 1987 0.75
99 Cellular immunotherapy: a new avenue in internal medicine. Acta Clin Belg 1998 0.75
100 Major depressive disorder, endogeneicity and natural killer cell numbers and activity. Int J Neurosci 1990 0.75
101 A MAGE-3 peptide presented by HLA-B44 is also recognized by cytolytic T lymphocytes on HLA-B18. Tissue Antigens 2002 0.75
102 Bispecific antibodies in lymphoma. Int Rev Immunol 1993 0.75
103 Loading of dendritic cells with antigen in vitro or in vivo by immunotargeting can replace the need for adjuvant. Adv Exp Med Biol 1993 0.75
104 Measured attenuation correction using the Maximum Likelihood algorithm. Med Prog Technol 1991 0.75
105 Detecting and estimating head motion in brain PET acquisitions using raw time-of-flight PET data. Phys Med Biol 2015 0.75
106 The use of the anti-malaria drug Fansidar (pyrimethamine and sulphadoxine) in the treatment of a patient with autoimmune lymphoproliferative syndrome and Fas deficiency. Br J Haematol 1998 0.75
107 Rapid processing of PET list-mode data for efficient uncertainty estimation and data analysis. Phys Med Biol 2016 0.75
108 CD80 (B7-1) and CD86 (B7-2): potential targets for immunotherapy? Res Immunol 1996 0.75
109 Autoimmune lymphoproliferative syndrome type III: an indefinite disorder. Leuk Lymphoma 2001 0.75
110 Dendritic cells can be used as physiological adjuvant in vivo. Adv Exp Med Biol 1995 0.75
111 Oncoselective transduction of CD80 and CD86 in tumor cell lines using an autonomous recombinant parvovirus. Anticancer Res 2000 0.75
112 [Education, status and future of the researcher]. Verh K Acad Geneeskd Belg 1992 0.75
113 Isotype switch and idiotype variation in hairy cell leukemia. Leukemia 1990 0.75
114 Interrelation of B lymphoid malignancies. Acta Clin Belg 1987 0.75
115 The T/B cell antigen, CD5, and the B-cell surface protein, CD72, form a pair of interacting receptors. Ann N Y Acad Sci 1992 0.75